Abstract library

2175 results for "Patient derived tumour xenografts".
#1107 The Chicken Chorioallantoic Membrane Assay as a Preclinical Model for the Research of Rare Gastrointenstinal Neuroendocrine Tumours
Introduction: Preclinical trials of cancer therapeutics require both in vitro and in vivo evaluations. For neuroendocrine tumours (NET) studies are limited to cell lines, thus xenograft models are needed for screening and evaluation of anti-cancer drugs. The chick chorioallantoic membrane (CAM) assay is a well-established model system to investigate tumour growth, angiogenesis and metastasis.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: ...none of the below
Presenting Author: PhD Nassim Ghaffari Tabrizi-Wizsy
Authors: Passegger C, Kump P, Haybäck J, Lipp R, ...
#2684 Tumour-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumour Patients after Curative Resection
Introduction: Non-functional pancreatic neuroendocrine tumours (NF-PanNETs) are steadily increasing in prevalence and present several clinical challenges.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Wuhu Zhang
Authors: Zhang W, Wang W, ...
#1648 Treatment Patterns and Survival Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden – A Population-Based Register-Linkage and Medical Chart Review Study
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is a group of neoplasms derived from the endocrine system in the GI tract and pancreas.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Åse Björstad
#3002 Quality of Life, Tumour Heterogeneity and Biomarker Levels in Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours: Baseline Data from CLARINET FORTE
Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof. Philippe Ruszniewski
#1263 Pretherapy Identification of Patients at Risk of Receiving a High Renal Dose Undergoing Peptide Receptor Radionuclide Therapy
Introduction: 68GaDOTA TATE imaging of patients with neuroendocrine tumours has shown that tumour sequestration is a major factor leading to a sink effect that decreases activity concentration in healthy tissues, particularly the renal parenchyma.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Steven Goodman
Keywords: dosimetry, PRRT
#2789 The Patient Journey – Experience from Symptoms to Diagnosis among Patients with Small Intestinal Neuroendocrine Tumours (SINET)
Introduction: Patients with SINET often have diffuse symptoms delaying diagnosis. In a patient survey it was observed that 1/3 of NET patients had a time span to diagnosis of > 5 years, with a median of 52 months. Here we assess the patients’ experience during that time period.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Study Coordinato Kajsa Oberg Holgersson
#3042 The Use of Total Parenteral Nutrition in a Series of Patients with Neuroendocrine Tumours in United Kingdom and the Netherlands
Introduction: There are controversies about the use of total parental nutrition (TPN) in patients with cancer. Currently data regarding TPN use in patients with neuroendocrine tumours (NETs) are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Dominique Clement
#1183 Establishment of a New Human Pancreatic Neuroendocrine Tumour Cell Line
Introduction: The development of new therapeutic strategies for patients with pancreatic neuroendocrine tumours is impaired by the paucity of suitable pre-clinical models. Although the two available tumour cell lines BON and QGP have a neuroendocrine phenotype, the proliferation rate is too high for a well differentiated neuroendocrine tumour.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Schrader J, Benten D, Rhotert C, Fahl M, ...
#2162 Single Cell Copy Number Variation Analysis (CNV) of Circulating Tumor Cells (CTCs) in Neuroendocrine Tumor (NET) Patients
Introduction: The identification and characterization of CTCs as part of a minimally invasive “liquid biopsy” provides an opportunity to explore NET biology, identify therapeutic targets and investigate tumour heterogeneity.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Alexa Childs
Authors: Childs A, Vesely C, Rizzo F M, Ensell L, ...